TrianglemiRisten (NCT07025564)
miRisten trial for Relapsed or Refractory Acute Myeloid Leukemia (NCT07025564). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with acute myeloid leukemia that has come back or has not responded to treatment.
The idea: give miRisten by vein. miRisten is designed to block miR-126, a small RNA molecule, and may stop cancer cells from growing by blocking molecules they need.
The study looks at safety, side effects, and the best dose.
This phase 1 study plans 20 patients. At City of Hope in Duarte, California, Amanda Blackmon leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.